Abstract
Introduction: epilepsy is a common neurological disorder, so exploring its treatment programs is of high significance. In this content, this work was developed to compare the effects of monotherapy with Carbamazepine (CBZ) and Levetiracetam (LEV) on coagulation factors and disease control in patients with partial-onset epilepsy (POE). Materials and Methods: in this work, 89 patients with POE diagnosed and treated at our hospital from January 2023 to January 2024 were enrolled. The patients were rolled into the CBZ group and the LEV group. Blood coagulation parameters were measured before and after treatment, and the frequency and severity of epileptic seizures were recorded for patients in different groups. Results: regarding coagulation factors, in the CBZ group, prothrombin time (PT), activated partial thromboplastin time (APTT), and D-dimer (D-D) levels at 1, 3, and 6 months after treatment were sharply lower in contrast to the pre-treatment levels, while changes in the LEV group were not obvious. Meanwhile, the fibrinogen (FIB) content after treatment was decreased in both groups. Furthermore, the frequency of epileptic seizures in all patients was reduced greatly after treatment, and difference in the control rate of frequency of epileptic seizure was not greatly different for patients in different groups. Conclusion: CBZ may increase the risk of coagulation abnormalities, but it was highly effective in controlling epileptic seizures. However, LEV had a smaller impact on coagulation and exhibited similar effect in controlling epileptic seizures.
Keywords
References
The published articles will be distributed under the Creative Commons Attribution 4.0 International License (CC BY). It is allowed to copy and redistribute the material in any medium or format, and remix, transform, and build upon it for any purpose, even commercially, as long as appropriate credit is given to the original author(s), a link to the license is provided and it is indicated if changes were made. Users are required to provide full bibliographic description of the original publication (authors, article title, journal title, volume, issue, pages), as well as its DOI code. In electronic publishing, users are also required to link the content with both the original article published in Journal of Medical Biochemistry and the licence used.
Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.